GeoVax Labs, Inc. Price & Performance (GOVX)

John N. Spencer Jr., a director at GeoVax Labs, recently acquired 10,000 company shares at $0.98 each, signaling his confidence in the firm’s prospects despite a challenging market. The purchase comes amid ongoing financial strain and increased R&D spending, but also underscores faith in GeoVax’s vaccine pipeline and funding strategies.12

GeoVax Labs was directed to stop work on a key Phase 2b COVID-19 vaccine trial after BARDA terminated the supporting contract. While the company maintains more cash than debt, the sudden halt introduces uncertainty about future funding and the company’s development timeline. GeoVax continues to pursue new partnerships and projects.23

GeoVax Labs shares dropped to a new 52-week low of $0.78, reflecting heightened volatility and investor concern. Despite brief gains, the stock has fallen nearly 50% over six months. The drop follows the suspension of a major vaccine trial and ongoing financial challenges, leaving the company’s recovery prospects uncertain.34